

Listing of Claims

The listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A method of treating atherosclerosis, comprising administering a therapeutically effective amount of a cysteinyl leukotriene 2 receptor antagonist to a patient in need of such treatment.

2. (Original) The method of Claim 1 wherein the cysteinyl leukotriene 2 receptor antagonist is a dual cysteinyl leukotriene 1 receptor antagonist and cysteinyl leukotriene 2 receptor antagonist.

3. (Original) The method of Claim 1 wherein the cysteinyl leukotriene 2 receptor antagonist is a selective cysteinyl leukotriene 2 receptor antagonist.

4. (Original) The method of Claim 1, wherein the cysteinyl leukotriene 2 receptor antagonist is selected from the group consisting of:

3-((carboxyacetal)amino)phenyl)thio)-4-nonyl-oxobenzenehexanoic acid, and
(2S, 3S, 2'S,3'S)-3,3'-[({3-[(E)-2-(7-chloroquinolin-2-yl)vinyl]phenyl}methylene)bis(thio)]bis(2-methylbutanoic acid.

5. (Original) A method for preventing or reducing the risk of atherosclerotic plaque rupture comprising administering a prophylactically effective amount of a cysteinyl leukotriene 2 receptor antagonist to a patient in need of such treatment.

6. (Original) The method of Claim 5 wherein the cysteinyl leukotriene 2 receptor antagonist is a dual cysteinyl leukotriene 1 receptor antagonist and cysteinyl leukotriene 2 receptor antagonist.

7. (Original) The method of Claim 5 wherein the cysteinyl leukotriene 2 receptor antagonist is a selective cysteinyl leukotriene 2 receptor antagonist.

8. (Original) The method of Claim 5, wherein the cysteinyl leukotriene 2 receptor antagonist is selected from the group consisting of:

3-((carboxyacetal)amino)phenyl)thio)-4-nonyl-oxobenzenehexanoic acid, and
(2S, 3S, 2'S,3'S)-3,3'-[({3-[(E)-2-(7-chloroquinolin-2-yl)vinyl]phenyl}methylene)bis(thio)]bis(2-methylbutanoic acid.

9. (Original) A method of treating an aortic aneurysm, comprising administering a therapeutically effective amount of a cysteinyl leukotriene 2 receptor antagonist to a patient in need of such treatment.

10. (Original) The method of Claim 9 wherein the cysteinyl leukotriene 2 receptor antagonist is a dual cysteinyl leukotriene 1 receptor antagonist and cysteinyl leukotriene 2 receptor antagonist.

11. (Original) The method of Claim 9 wherein the cysteinyl leukotriene 2 receptor antagonist is a selective cysteinyl leukotriene 2 receptor antagonist.

12. (Original) The method of Claim 9, wherein the cysteinyl leukotriene 2 receptor antagonist is selected from the group consisting of:

3-((carboxyacetal)amino)phenylthio)-4-nonyl-oxobenzenehexanoic acid, and
(2S, 3S, 2'S,3'S)-3,3'-[({3-[(E)-2-(7-chloroquinolin-2-yl)vinyl]phenyl}methylene)bis(thio)]bis(2-methylbutanoic acid.

13. (Original) A method of treating pulmonary fibrosis, comprising administering a therapeutically effective amount of a cysteinyl leukotriene 2 receptor antagonist to a patient in need of such treatment.

14. (Original) The method of Claim 13 wherein the cysteinyl leukotriene 2 receptor antagonist is a dual cysteinyl leukotriene 1 receptor antagonist and cysteinyl leukotriene 2 receptor antagonist.

15. (Original) The method of Claim 13 wherein the cysteinyl leukotriene 2 receptor antagonist is a selective cysteinyl leukotriene 2 receptor antagonist.

16. (Original) The method of Claim 13, wherein the cysteinyl leukotriene 2 receptor antagonist is selected from the group consisting of:

3-((carboxyacetal)amino)phenylthio)-4-nonyl-oxobenzenehexanoic acid, and
(2S, 3S, 2'S,3'S)-3,3'-[({3-[(E)-2-(7-chloroquinolin-2-yl)vinyl]phenyl}methylene)bis(thio)]bis(2-methylbutanoic acid.

17. (Original) A method of treating cerebral edema, comprising administering a therapeutically effective amount of a cysteinyl leukotriene 2 receptor antagonist to a patient in need of such treatment.

18. (Original) The method of Claim 17 wherein the cysteinyl leukotriene 2 receptor antagonist is a dual cysteinyl leukotriene 1 receptor antagonist and cysteinyl leukotriene 2 receptor antagonist.

19. (Original) The method of Claim 17 wherein the cysteinyl leukotriene 2 receptor antagonist is a selective cysteinyl leukotriene 2 receptor antagonist.

20. (Original) The method of Claim 17, wherein the cysteinyl leukotriene 2 receptor antagonist is selected from the group consisting of:
3-((carboxyacetal)amino)phenylthio)-4-nonyl-oxobenzenehexanoic acid, and
(2S, 3S, 2'S,3'S)-3,3'-[({3-[(E)-2-(7-chloroquinolin-2-yl)vinyl]phenyl}methylene)bis(thio)]bis(2-methylbutanoic acid).